MASH screening in type 2 diabetes

A new cost-utility analysis finds that staged, non-invasive screening strategies for metabolic dysfunction-associated steatohepatitis, or MASH, were cost-effective compared with no screening in hypothetical cohorts of adults with type 2 diabetes in the United States, the United Kingdom, and four other European countries. That is a policy and service-design finding, not a result showing that screening itself improves an individual person's health. The study compared modelled outcomes rather than following patients through a screening programme.^[1]

Why type 2 diabetes is central to the question

MASH is the inflammatory form of metabolic dysfunction-associated steatotic liver disease, or MASLD. Fibrosis means scarring in the liver, and advanced fibrosis is the part of the spectrum that is most relevant to liver-related outcomes. The EASL-EASD-EASO guideline says case-finding with non-invasive tests should be used for people with cardiometabolic risk factors, particularly people with type 2 diabetes or obesity plus another metabolic risk factor. That is different from recommending a universal test for every adult.^[2]

The guideline's logic is practical: liver disease can progress with few obvious symptoms, while type 2 diabetes identifies a group with enough baseline risk to make structured assessment worth considering in clinical systems. It does not turn a diagnosis of diabetes into proof that someone has MASH or fibrosis. It identifies who may need a clinician-led assessment of liver risk.^[2]

What the new model compared

The September 2026 paper used a decision-analytic Markov model, a method that estimates how a hypothetical population may move between health states over time. It compared five multi-step, non-invasive testing strategies with no screening across six countries. The authors report that the strategies used blood-based and imaging tests rather than treating liver biopsy as the starting point for everyone.^[1]

In the model, at least one multi-step strategy dominated no screening in Germany, France, Italy, and the United States. Across all six settings, the reported incremental cost-effectiveness ratios ranged from dominance to £18,572 per quality-adjusted life-year gained. A quality-adjusted life-year is an economic measure that combines length of life with health-related quality of life. These figures describe the model's assumptions and inputs, not a price list or a promise about care in any one country.^[1]

Why the sequence of tests matters

The study's headline is not that every person with diabetes should have a biopsy. In fact, screening strategies involving liver biopsy were dominated by no screening in every setting in the model. The paper instead favoured multi-step non-invasive approaches. In health-economic language, a dominated option costs more and produces worse outcomes than the comparison used in that model.^[1]

That broad direction matches the EASL-EASD-EASO guideline, which describes a stepwise route using a blood-based score such as FIB-4, followed by imaging such as transient elastography when appropriate. FIB-4 is a calculation based on routine clinical information that helps estimate fibrosis risk. Transient elastography is an ultrasound-based measurement that estimates liver stiffness. The guideline does not make this article a substitute for interpreting either result.^[2]

What the analysis does not establish

This is a cost-utility analysis, not a randomised screening trial. Its results depend on model inputs, including testing pathways, costs, uptake, disease progression, and how each health system delivers care. The authors used sensitivity analyses to test uncertainty, reporting a 90% to 100% probability of cost-effectiveness for multi-step strategies across the countries examined. That strengthens the modelled result, but it does not erase the difference between a simulation and observed outcomes from a live programme.^[1]

It also does not tell an individual reader whether they have MASLD, MASH, or fibrosis, nor does it prescribe a test or treatment. Access, referral pathways, reimbursement, and local guidance differ between countries and health systems. A clinician can place liver-risk information alongside medical history, blood results, medicines, alcohol intake, and other relevant facts.^[2]

Where semaglutide fits, and where it does not

The EASL-EASD-EASO guideline names incretin-based therapies, including semaglutide and tirzepatide, for type 2 diabetes or obesity when indicated. That is not the same as saying that a screening model proves a treatment effect, or that these medicines are MASH treatments for every person with diabetes. The separate tirzepatide regulatory context remains relevant to medicine access, not to the screening result. For the medication evidence and safety context, see our semaglutide overview.^[2]

The useful takeaway from this paper is narrower. It gives payers, health systems, and guideline writers a new modelled argument for staged, non-invasive liver-risk assessment in adults with type 2 diabetes. It does not offer a self-screening protocol. Readers looking at medicine access or legal status can review semaglutide regulation by country, then discuss personal screening or treatment questions with a qualified healthcare professional.^[1]

What we do not yet know

The paper itself calls for research on longer-term care and the economic effects of emerging MASH therapies. We also do not know whether every healthcare system can reproduce the modelled pathways when test availability and follow-up capacity are uneven. Cost-effectiveness can help shape policy, but it is not a diagnosis and it cannot settle a personal medical decision.^[1]